Two Shots. $40. Everywhere.

A gamechanger in HIV prevention is here: Lenacapavir (LEN) is an injectable medication that only needs to be given twice a year and is nearly 100 percent effective. This breakthrough is especially valuable for people who face higher HIV risk, like those living in places where Doctors Without Borders teams operate.

Gilead, the manufacturer, sells LEN for $28,000 per patient annually in the US and severely restricts its supply to certain countries. Gilead also refuses to sell LEN directly to Doctors Without Borders.

A medical breakthrough like LEN should be available everywhere. Now.

We are calling on Gilead to reduce the price of LEN to less than $40 per person per year, increase its supply to match actual global demand, and sell LEN directly to Doctors Without Borders and other organizations.

HIV isn’t waiting – why is Gilead? Join our campaign calling for access to LEN for all!

Add Your Name:

First Name

Last Name

Tell us more about why access to medicine is important to you.

I understand and agree that by signing this petition, my name, along with the names of other signatories, will be shared with Gilead Sciences, calling for greater global access to the HIV prevention drug lenacapavir.

I understand and agree that if I complete the comment section, my sentiments will be shared with Gilead Sciences without attribution. Further, I understand I am giving MSF USA permission to use my comment solely for campaign-related materials, also without attribution.

I would like to receive regular email updates on MSF USA's medical humanitarian work. I understand I can update or change my preferences by clicking here or calling MSF USA at (888) 392-0392. I can also unsubscribe at any time. By opting into MSF USA communications, I am agreeing to MSF USA's privacy policy. Read our privacy policy for more information.